Economic Impact of Ambulatory Clinical Pharmacists in an Advanced Heart Failure Clinic. Issue 11 (November 2022)

• Record Type: Journal Article
• Authors: Kido, Kazuhiko; Colvin, Bailey M.; Broscious, Rachael; Bongiorni, Sydney; Sokos, George; Kamal, Khalid M.
• Is Part Of: Annals of pharmacotherapy. Volume 56:Issue 11(2022)
• Page Start: 1203
• Page End: 1209
• Publication Date: 2022-11
• Subjects: pharmacist -- pharmacy -- heart failure -- economic -- outcome; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.5805
• DOI: 10.1177/10600280221075755
• Languages: English
• ISSNs: 1060-0280

Abstract

Background: Clinical pharmacists play pivotal roles in multidisciplinary heart failure (HF) teams through the management of HF pharmacotherapy, but no study has examined the economic impact of HF ambulatory clinical pharmacists in an advanced HF clinic. Objective: The objective of the study was to evaluate the economic impact of HF ambulatory clinical pharmacist interventions in an advanced HF clinic using a cost-benefit analysis. Methods: This prospective observational study detailed HF ambulatory clinical pharmacist interventions over 6 months in an advanced HF clinic in a single-center tertiary teaching hospital. The economic impact of the interventions was estimated based on the indirect cost savings with pharmacist interventions and direct cost savings recommendations. A cost-benefit analysis was performed to assess the cost of delivering the interventions compared with the benefits generated by clinical pharmacists. Results were reported as a benefit-cost ratio and net benefits. Results: HF ambulatory clinical pharmacists made a total of 2, 361 provider-accepted interventions over 6 months. Overall, the 3 most common intervention types were medication reconciliation (28.7%), dose change (20.8%), and addition of medication (12.3%). Anticoagulation (21.2%) was the most common intervened class of medication, followed by sodium-glucose cotransporter-2 inhibitor (12.3%) and angiotensin receptor neprilysin inhibitor (9.2%). The total net benefits were $55, 553.24 over 6 months and the benefit-cost ratio was 1.55. Conclusion and Relevance: The addition of cardiology clinical pharmacists to an advanced HF clinic may be financially justified and cost-beneficial.